Cordyceps cicadae composite medicine for treating diabetic nephropathy and preparation method thereof

Abstract

The invention provides cordyceps cicadae composite medicine for treating diabetic nephropathy and a preparation method thereof and belongs to the field of traditional Chinese medicine. The cordyceps cicadae composite medicine for treating diabetic nephropathy is prepared from the following raw materials in parts by weight: 18 to 22 parts of cordyceps cicadae, 14 to 16 parts of radix rehmanniae, 14to 16 parts of common yam rhizome, 8 to 12 parts of fructus lycii, 8 to 12 parts of fructus corni, 8 to 12 parts of achyranthes root, 14 to 16 parts of fried radix astragali seu hedysari, 8 to 12 parts of radix salvia miltiorrhizae, 8 to 12 parts of poria with hostwood and 5 to 7 parts of chamomile flower. The composite medicine has scientific and rigovous compatibility and complete assistant andguide and has the effects of tonifying qi and yin, promoting blood circulation to remove blood stasis, nourishing liver and kidney and can achieve an effect of treating both symptoms and root causeson the diabetic nephropathy. Research data show that aqueous extract of the cordyceps cicadae composite medicine can effectively inhibit aldose reductase and reduce expression of TGF-beta1 protein, alpha-SMA protein and FN protein of renal tubular epithelial cells; thus, damage to the glomerulus cells is reduced, glomerular sclerosis is relieved, tubular interstitial fibrosis is inhibited, pathological change of the kidney is lightened, illness state development can be inhibited and converted, and a better treating and protecting effect on the diabetic nephropathy is achieved.

Description

Technical field [0001] The invention relates to the field of traditional Chinese medicine, in particular to a golden cicada flower prescription medicine for treating diabetic nephropathy and a preparation method thereof. Background technique [0002] Diabetic nephropathy (DN) is a type of microvascular complications and one of the most serious complications of diabetes. DN can eventually develop into end-stage renal disease (ESRD) after chronic renal insufficiency, and its incidence is increasing year by year. The incidence of type I diabetes (T1DM) DN is 30%-40%, and type II diabetes (T2DM) is 15%. ~20%. In European and American countries, DN has become the primary cause of chronic renal failure (chronic renal failure, CRF) for hemodialysis and kidney transplantation. In the United States, patients with ESRD due to DN account for about 40% of all ESRD cases; in my country, DN accounts for about 8% of ESRD, and some economically developed areas have reached 15%. [0003] The pat...

AI Technical Summary

Problems solved by technology

Once clinical proteinuria occurs, there is no effective way to reverse renal damage. Most patients will be transferred to CRF after a few years, and the effect of dialysis or kidney transplantation is worse than that of non-diabetic patients. At the same time, the high cost of treatment also makes the majority of patients daunting

At the same time, modern medicine has no specific treatment for DN, and there are few treatment methods. At present, it is mainly based on its risk factors, such as controlling diet, blood pressure, blood sugar, blood lipids, reducing urine protein, antithrombotic and other comorbidities and complications.

Images